INmune Bio (NASDAQ:INMB) Releases Earnings Results, Beats Expectations By $0.07 EPS

INmune Bio (NASDAQ:INMB) posted its quarterly earnings data on Monday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.07, FiscalAI reports.

Here are the key takeaways from INmune Bio’s conference call:

• CORDStrom is the company’s lead value driver and the team says it will file a U.K. MAA by mid‑summer 2026 (with subsequent EMA and U.S. BLA filings later in 2026), supported by reproducible batch manufacturing, defined potency assays/MOA, and clinical data showing wound healing, itch reduction, QoL improvements and a favorable safety profile.
• While management highlights encouraging biomarker and subgroup signals for XPro and an FDA alignment on a two‑stage adaptive Phase III, the MINDFuL Phase II did not meet its top‑line primary endpoint (leading to a $16.5M intangible‑asset impairment) and the program will require additional partner funding to advance.
• The company reported $24.8M in cash at year‑end 2025 and believes this funds operations only through Q1 2027, implying near‑term financing or partnership needs given ongoing development plans and a net loss of $45.9M for 2025.
• INKmune’s Phase II in metastatic castration‑resistant prostate cancer was completed ahead of schedule and under budget, meeting its primary endpoint and two of three secondary endpoints, which management positions as de‑risking that program.

INmune Bio Price Performance

Shares of NASDAQ:INMB traded up $0.02 during midday trading on Monday, hitting $1.14. 390,757 shares of the company’s stock were exchanged, compared to its average volume of 433,561. INmune Bio has a 12 month low of $1.10 and a 12 month high of $11.64. The company has a market cap of $30.31 million, a PE ratio of -0.54 and a beta of 0.77. The stock has a 50 day moving average price of $1.42 and a 200-day moving average price of $1.65.

Analysts Set New Price Targets

A number of equities research analysts have commented on INMB shares. Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Lucid Cap Mkts raised INmune Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, INmune Bio currently has an average rating of “Hold” and an average target price of $8.00.

Hedge Funds Weigh In On INmune Bio

A number of hedge funds have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd bought a new stake in INmune Bio during the 4th quarter worth approximately $26,000. Intech Investment Management LLC purchased a new position in shares of INmune Bio during the second quarter valued at approximately $26,000. Squarepoint Ops LLC purchased a new position in shares of INmune Bio during the third quarter valued at approximately $30,000. Virtu Financial LLC bought a new stake in INmune Bio during the fourth quarter worth $32,000. Finally, Wells Fargo & Company MN grew its holdings in INmune Bio by 79.0% during the fourth quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock worth $39,000 after buying an additional 10,970 shares in the last quarter. Institutional investors and hedge funds own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.